Prof. PeptideProf. Peptide

MOTS-c

Metabolic & GLP-1Research-Grade

Last reviewed: September 20, 2026

Quick Facts

What it is
A peptide encoded inside the mitochondrial genome itself — a mitochondria-derived signal studied for insulin sensitivity, metabolism, muscle preservation, exercise capacity, and mitochondrial aging.
How it's taken
Subcutaneous injection, once daily (morning, often pre-workout); a nasal-spray format is also sold
Half-life
Not well characterized in humans; dosed once daily by convention
Typical research dose
5–10 mg subcutaneously once daily, in 4–12 week cycles
Research status
Not FDA-approved — research use only. Phase 2 trial recruiting; no results yet.
On this page
  1. 1.Where to source MOTS-c
  2. 2.What is MOTS-c?
  3. 3.How does MOTS-c work?
  4. 4.What is MOTS-c used for?
  5. 5.How long does MOTS-c take to work?
  6. 6.How is MOTS-c dosed?
  7. 7.How is MOTS-c administered?
  8. 8.What does MOTS-c stack well with?
  9. 9.What are the side effects of MOTS-c?
  10. 10.Does MOTS-c interact with other drugs?
  11. 11.How should MOTS-c be stored?
  12. 12.What are the limitations of MOTS-c research?
  13. 13.MOTS-c FAQ
  14. 14.References
  15. 15.Published Studies
  16. 16.In the News

Where to source MOTS-c

MOTS-c is not FDA-approved and is sold only as a research-grade peptide. The vendors highlighted below have been vetted for transparent third-party testing, traceable batch documentation, and verified discount codes — including a nasal-spray format option that's interesting for the metabolic research context.

Capstone Peptides50% off
Professor's Pick

Accumark Labs · digital COAs

Shop Capstone Peptides
Amino Club40% off

ILS Laboratories · batch COAs

Shop Amino Club
Peptide Partners10% off
Professor's Pick

Kovera, Chromate and BioRegen · certificates checked at each lab

Shop Peptide Partners
Glacier Aminos10% off

Batch-traceable COAs · cold-chain shipping

Shop Glacier Aminos
Compare prices across 59 vendors

Also stocking MOTS-c

Aero Peptides, Ameano Peptides, Ascension Peptides, BioCollex — each carries a current price row for this compound.

Compare all 59 vendors stocking MOTS-c

See all 88 verified vendors · Compare every vendor's MOTS-c price

What is MOTS-c?

MOTS-c (short for Mitochondrial ORF of the 12S rRNA Type-c, sometimes written MOTSc) is a 16-amino-acid peptide encoded inside the mitochondrial genome itself — making it one of the first known mitochondria-derived peptides. Classed as a Mitochondrial-Derived Peptide (MDP) and often described as an AMPK activator or exercise mimetic. Discovered in 2015 at USC, it acts as a hormone-like signal from mitochondria to the rest of the body, regulating metabolism through AMPK pathways (the same master energy regulator activated by metformin and exercise). Research interest has focused on insulin resistance, type 2 diabetes, muscle preservation, and cellular aging. MOTS-c blood levels naturally decline with age, which has made it a candidate for longevity research. New to peptide research? Start with the basics

Reported benefits:

  • Improved insulin sensitivity and glucose uptake in skeletal muscle (preclinical)
  • AMPK pathway activation similar to metformin and exercise
  • Reduced muscle wasting through suppression of myostatin signaling
  • Cardiovascular protection in diabetic models
  • Potential anti-aging effects through mitochondrial function support

Common research dose: MOTS-c is in early-stage clinical research. Animal studies use 0.5–15 mg/kg/day. Common research-grade human dose is 5–10 mg subcutaneously once daily, though there is no validated clinical dosing standard.

Where to buy: PP maintains a vetted list of peptide vendors with verified discount codes. See Verified Discount Codes for current options.

How does MOTS-c work?

MOTS-c activates AMPK (AMP-activated protein kinase), the same master energy regulator activated by metformin and exercise. It's encoded inside the mitochondrial genome itself (12S rRNA region) and acts as a retrograde signal from mitochondria to the nucleus, regulating which nuclear genes are expressed during metabolic stress. The mitochondrial origin is unique among research peptides and is why MOTS-c sits at the intersection of metabolic and longevity research.

  1. AMPK Pathway Activation [1]. MOTS-c activates AMPK (AMP-activated protein kinase), a master regulator of cellular energy. AMPK activation is the same pathway used by metformin and triggered by exercise, leading to increased glucose uptake and improved metabolism.
  2. Mitochondrial Communication [2]. MOTS-c is encoded in the mitochondrial genome (12S rRNA region) and acts as a retrograde signal from mitochondria to the nucleus. It regulates which nuclear genes are expressed during metabolic stress.
  3. Skeletal Muscle Glucose Uptake [1]. In skeletal muscle, MOTS-c upregulates GLUT4 expression and enhances insulin-independent glucose uptake. This is a primary mechanism for the insulin sensitivity improvements observed in animal models.
  4. Muscle Atrophy Prevention [3]. MOTS-c reduces myostatin (a negative regulator of muscle mass) and other muscle-wasting signaling. In animal studies, it prevented atrophy associated with aging and metabolic disease.
  5. Cardiac Function Restoration [4]. In rat models of type 2 diabetic heart disease, daily MOTS-c (15 mg/kg for 3 weeks) restored mitochondrial respiration and reduced left ventricular wall thickness.

What is MOTS-c used for?

MOTS-c's research evidence base spans type 2 diabetes and insulin sensitivity (the originating area), mitochondrial disease (MELAS syndrome), sarcopenia and muscle aging, cardiovascular disease in diabetic models, and pancreatic beta-cell senescence. A Phase 2 trial of MOTS-c (NCT07505745) is recruiting, with no results yet. The bulk of evidence remains animal and cell-based.

  1. Type 2 Diabetes [1][5]. MOTS-c improves insulin sensitivity in animal models. Human studies show MOTS-c blood levels are lower in T2D, gestational diabetes, and obese children. A Phase 2 placebo-controlled trial of MOTS-c in adults with prediabetes and overweight or obesity is recruiting, with no results yet [6].
  2. Mitochondrial Disease [2]. Investigated for MELAS syndrome (mitochondrial encephalopathy), a severe genetic mitochondrial disorder. Effects on mtDNA mutation models are mixed.
  3. Sarcopenia and Muscle Aging [3]. Reduces myostatin, prevents muscle atrophy in obesity and aging models. Of interest for age-related muscle loss.
  4. Cardiovascular Disease [4]. Restores mitochondrial respiration in diabetic heart tissue. May offer cardioprotective effects via NRG1-ErbB4 pathway.
  5. Pancreatic Beta-Cell Senescence [5]. A 2025 Experimental & Molecular Medicine study showed MOTS-c reduces beta-cell senescence in aged mice, slowing glucose intolerance progression.

How long does MOTS-c take to work?

MOTS-c is mechanism-driven rather than producing dramatic short-term effects. In animal studies, daily dosing for 3 weeks restored mitochondrial function. Human clinical effects are not well characterized. Most users report subtle changes in energy and recovery rather than acute effects — consistent with a mitochondrial-function-restoration mechanism rather than acute appetite suppression or hormonal stimulation.

MOTS-c is mechanism-driven rather than producing dramatic short-term effects. In animal studies, daily dosing for 3 weeks restored mitochondrial function. Human clinical effects are not well characterized. Most users report subtle changes in energy and recovery rather than acute effects — consistent with a mitochondrial-function-restoration mechanism rather than acute appetite suppression or hormonal stimulation. Effects in research protocols accumulate over 4–12 weeks of consistent daily dosing.

How is MOTS-c dosed?

No human trial of MOTS-c itself has posted results — FDA's page on bulk drug substances that may present significant safety risks in compounding states that FDA "has not identified any human exposure data on drug products containing MOTs-C administered via any route of administration." The figures below separate the one published animal study from community-reported human figures.

Prof. Peptide reports what trials established and what research communities practice, labelled separately. Neither is a recommendation.

Need to calculate a dose?

Use the Prof. Peptide dosage calculator for accurate reconstitution and dosing math.

Open Calculator

What the cited literature administered (Animal Model)

Lee et al. 2015 (Cell Metab, PMID 25738459), the study that first identified MOTS-c, used two separate intraperitoneal mouse arms: 5 mg/kg/day for 7 days in C57BL/6 mice, which improved insulin sensitivity on glucose-tolerance testing; and 0.5 mg/kg/day for 8 weeks in CD-1 mice on a high-fat diet, which prevented diet-induced obesity and restored glucose tolerance. These are mouse doses from a specific published study, reported as such, not converted into a human figure. A Phase 2 trial of MOTS-c itself (NCT07505745, subcutaneous, once daily, 12 weeks, in adults with prediabetes and overweight or obesity, N=120 planned) is currently recruiting with no results yet.

Community-reported practice (unverified)

  1. Standard research-grade dose. 5–10 mg subcutaneously once daily — a flat human dose, not derived from the animal study's own body-weight-based figures.
  2. Maintenance protocols. Some protocols use 5 mg twice weekly for maintenance.
  3. Cycle length. 4–12 weeks is common; some longevity protocols use extended use.

MOTS-c is one of the largest peptides commonly used at this dose range, which makes per-dose cost relatively high compared to smaller peptides like BPC-157 or TB-500.

The Prof. Peptide dosage calculator converts between milligram figures and syringe units for a given reconstitution; it performs the arithmetic and does not set a schedule. The MOTS-c reconstitution calculator works the same arithmetic against the vial sizes tracked for this compound.

How is MOTS-c administered?

MOTS-c is given as a subcutaneous injection — under the skin, not into muscle — once daily using a small insulin syringe. Morning dosing is most common in research protocols, often before exercise (since endogenous MOTS-c is exercise-induced). For the practical mechanics of insulin syringes, units vs mcg conversion, and subcutaneous technique, see the syringes and injection technique guide.

  1. Route. Subcutaneous injection, once daily. Common sites: abdomen, thigh, upper arm.
  2. Time of day. Morning dosing is most common, often before exercise where used in metabolic research — aligns with endogenous exercise-induced MOTS-c release.
  3. With or without food. Either is fine; no fasting requirement.
  4. Site rotation. Rotating sites each day is the convention for limiting localized irritation.
  5. Missed dose. The reported practice is to administer if less than 12 hours late, and otherwise to skip to the next scheduled day.
  6. Cycle structure. 4–12 weeks typical; some longevity protocols use extended cycles.

Timing context. MOTS-c is endogenously exercise-induced — skeletal muscle MOTS-c levels rise 11.9-fold after exercise in humans. Research-grade administration aligned with training (morning, pre-workout) is a deliberate choice to layer exogenous dosing onto the natural exercise-induced pulse. The pharmacokinetic profile of exogenous MOTS-c in humans is not well characterized.

AspectReported
FrequencyOnce daily; a 4–12 week cycle is reported community practice, not derived from a trial or label; Prof. Peptide has not independently verified it.
Best time of dayMorning, often pre-workout to align with endogenous exercise-induced MOTS-c pulse
FoodNo fasting required; inject with or without food
Injection site rotationRotating between the abdomen, thigh, and upper arm without reusing the same site for the next injection is standard subcutaneous-injection practice — documented in FDA-approved injectable labels generally (e.g., Wegovy's and Mounjaro's own instructions to rotate with each dose), not specific to MOTS-c.
Half-lifeNot well characterized in humans; once-daily dosing is research convention
Steady-stateEffects accumulate over weeks of daily dosing — mitochondrial-function restoration is gradual

Reconstitution math. Water volume sets concentration: a lower volume yields a higher concentration and a smaller syringe draw for a given mg amount, and the reverse for a higher volume. MOTS-c research vials are typically 10 mg. Because per-dose amounts are large (5–10 mg), 1 mL reconstitution keeps syringe draws within insulin syringe capacity. All units below are measured on a U-100 insulin syringe (100 units = 1 mL). The table assumes a 10 mg vial.

BAC waterConcentration1 mg dose2.5 mg dose5 mg dose10 mg dose
1 mL10 mg/mL10 units25 units50 units100 units
2 mL5 mg/mL20 units50 units100 unitsn/a*
3 mL3.33 mg/mL30 units75 unitsn/a*n/a*

*Draw exceeds standard 100-unit insulin syringe capacity at this reconstitution volume — would require split injections or a lower reconstitution volume.

Units vs mcg. At a 10 mg vial, each unit drawn delivers 100 mcg of MOTS-c at 1 mL reconstitution, 50 mcg at 2 mL, and 33 mcg at 3 mL — the reconstitution volume determines the mcg-per-unit conversion. For a primer on reading insulin syringes and choosing the right barrel size, see our guide on syringes and injection technique.

What does MOTS-c stack well with?

MOTS-c is most commonly used standalone in research. Notable pairings include NAD+ precursors (NMN, NR) for mitochondrial-focused research, GLP-class drugs (semaglutide, tirzepatide, retatrutide) for muscle preservation during rapid weight loss (theoretical based on myostatin suppression — no clinical validation), and resistance training (which is the natural endogenous trigger). Metformin shares the AMPK activation pathway — combined use is theoretical.

  1. Standalone use. Most common in MOTS-c research.
  2. NAD+ precursors. NAD+ and NMN/NR are combined in mitochondrial-focused research; both target mitochondrial function through different pathways.
  3. GLP-class drugs. Semaglutide, tirzepatide, retatrutide proposed combination during weight loss to preserve muscle mass via MOTS-c's myostatin-suppressing effect, though no clinical data validates this combination.
  4. Resistance training. Natural pairing since endogenous MOTS-c levels rise 11.9-fold with exercise — exogenous MOTS-c amplifies the exercise-induced metabolic benefits.
  5. Metformin. Mechanistic overlap (both activate AMPK), so combined use is theoretical rather than established.

What are the side effects of MOTS-c?

MOTS-c has limited human clinical data. The peptide is endogenously produced, which suggests low immunogenicity, but long-term exogenous administration safety has not been established. The most-reported user effects are mild injection-site reactions. Mild headache and fatigue are uncommon. No documented serious adverse events at researched doses, but the data set is small.

Common (most users)

  1. Injection site reactions. Minor — mild redness or irritation.
  2. No common systemic effects. Most users report no acute systemic effects.

Less common (moderate)

  1. Mild headache. Inconsistent across users.
  2. Fatigue. Inconsistent across users.
  3. Nausea. Uncommon.

Serious (rare)

  1. Long-term safety data limited. Most evidence is preclinical.
  2. Severe allergic reactions. Theoretical, not commonly reported.

MOTS-c has limited human clinical data. The peptide is endogenously produced, which suggests low immunogenicity, but long-term exogenous administration safety has not been established.

Does MOTS-c interact with other drugs?

MOTS-c's relevant interactions are with diabetes medications (theoretically lower insulin or sulfonylurea requirements over time as insulin sensitivity improves — monitor blood glucose), metformin (overlapping AMPK pathway), and mitochondrial-targeted therapies (NAD+ precursors, CoQ10 — mechanism overlap, research-stage). No major drug interactions reported in early human clinical exposure.

  1. Diabetes medications. MOTS-c may improve insulin sensitivity in animal models, theoretically lowering insulin or sulfonylurea requirements over time. Blood glucose is what reported protocols monitor.
  2. Metformin. Overlapping AMPK activation pathway; theoretical synergy but no clinical validation.
  3. Mitochondrial-targeted therapies (NAD+ precursors, CoQ10). Overlap in mechanism; combined use is research-stage.
  4. No major drug interactions reported in early human clinical exposure.

How should MOTS-c be stored?

  1. Lyophilized (powder) form: Store at 2–8°C sealed; freeze at -20°C for long-term storage.
  2. Reconstituted solution: 2–8°C, refrigerated, is standard practice once dissolved. Prof. Peptide has not identified a manufacturer label, published study, or lab document establishing how long reconstituted research-grade MOTS-c remains stable — this page does not state a duration as fact.
  3. Reconstitution uses bacteriostatic water for injection (BAC water). Swirl gently — do not shake.
  4. MOTS-c is stored protected from light.
  5. A solution that is cloudy, discolored, or contains particles is discarded.

What are the limitations of MOTS-c research?

MOTS-c is investigational and not approved by the FDA, EMA, or any major regulatory body for therapeutic use. A Phase 2 placebo-controlled trial (NCT07505745) began recruiting in February 2026 and has no results yet; no completed human efficacy trial was found. A completed Phase 1 trial of CB4211 (NCT03998514) posted no results, and its registry record does not state that CB4211 is MOTS-c. The bulk of research evidence remains in animal models and cell-based studies. MOTS-c is named on the WADA Prohibited List (2025 and 2026 lists) under S4.4.1, activators of AMP-activated protein kinase, prohibited at all times (in- and out-of-competition).

MOTS-c is investigational and not approved by the FDA, EMA, or any major regulatory body for therapeutic use. A Phase 2 placebo-controlled trial (NCT07505745) began recruiting in February 2026 and has no results yet; no completed human efficacy trial was found. A completed Phase 1 trial of CB4211 (NCT03998514) posted no results, and its registry record does not state that CB4211 is MOTS-c. The bulk of research evidence remains in animal models and cell-based studies.

Long-term human safety data is limited. FDA’s bulk-substance safety page states that compounded MOTS-c may pose risk for immunogenicity for certain routes of administration, and long-term exogenous administration safety has not been established. MOTS-c is named on the WADA Prohibited List (2025 and 2026 lists) under S4.4.1, activators of AMP-activated protein kinase, prohibited at all times (in- and out-of-competition).

Research-grade MOTS-c sold by specialty peptide vendors is intended for laboratory research use only and is not approved for human consumption.

MOTS-c FAQ

What is MOTS-c?

MOTS-c is a 16-amino-acid peptide encoded inside the mitochondrial genome itself, making it one of the first known mitochondria-derived peptides. Discovered at USC in 2015, it acts as a hormone-like signal from mitochondria to the rest of the body, regulating metabolism through AMPK pathways.

How does MOTS-c improve insulin sensitivity?

MOTS-c activates AMPK in skeletal muscle, which is the same pathway used by metformin and triggered by exercise. It also upregulates GLUT4 expression, which enhances glucose uptake into muscle cells. In animal studies, this translates to measurably improved insulin sensitivity, especially in obesity and type 2 diabetes models.

Is MOTS-c FDA-approved?

No. MOTS-c is investigational and sold only as a research-grade peptide for laboratory use. A Phase 2 placebo-controlled trial of MOTS-c (NCT07505745, 12 weeks, 120 adults planned) began recruiting in February 2026 and has no results yet. No completed human efficacy trial of MOTS-c was found.

Does MOTS-c help with weight loss?

Indirectly. MOTS-c improves metabolism through AMPK activation rather than appetite suppression. It does not produce GLP-class weight loss like semaglutide or tirzepatide. Its primary use cases are improving insulin sensitivity, preserving muscle mass, and supporting mitochondrial function rather than direct weight reduction.

Can MOTS-c help preserve muscle during weight loss?

Possibly. Animal studies show MOTS-c reduces myostatin (a negative regulator of muscle mass) and prevents atrophy in obesity and aging models. This has led to research interest in pairing MOTS-c with GLP-class drugs to preserve lean tissue during rapid weight loss, though no controlled human data validates this combination.

Is MOTS-c safe?

Limited human safety data exists. FDA’s bulk-substance safety page states that compounded MOTS-c may pose risk for immunogenicity for certain routes of administration. Animal studies have not reported significant toxicity at researched doses. Long-term human exogenous administration safety has not been established.

What is the connection to anti-aging research?

MOTS-c blood levels naturally decline with age, and the peptide supports mitochondrial function — both linked to aging biology. A 2025 Experimental & Molecular Medicine study showed MOTS-c reduces pancreatic beta-cell senescence in aged mice, slowing glucose intolerance progression. This is hypothesis-generating, not clinically established.

Where can I buy MOTS-c?

MOTS-c is sold by specialty research peptide vendors. PP maintains a list of vetted vendors with verified discount codes — see Verified Discount Codes .

References

  1. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-54. https://www.cell.com/article/S1550-4131(15)00061-3/fulltext
  2. Kim SJ, Mehta HH, Wan J, et al. Mitochondrial peptides modulate mitochondrial function during cellular senescence. Aging (Albany NY). 2018;10(6):1239-56.
  3. Kumagai H, Coelho AR, Wan J, et al. MOTS-c reduces myostatin and muscle atrophy signaling. Am J Physiol Endocrinol Metab. 2021;320(4):E680-90. https://journals.physiology.org/doi/full/10.1152/ajpendo.00275.2020
  4. Pham AH, Wei Y, Koleva M, et al. Mitochondria-derived peptide MOTS-c restores mitochondrial respiration in type 2 diabetic heart. Front Physiol. 2025. https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2025.1602271/full
  5. Kong BS, Lee H, L'Yi S, Hong S, Cho YM. Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes. Exp Mol Med. 2025;57(8):1861-1877. https://www.nature.com/articles/s12276-025-01521-1
  6. MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity, NCT07505745. https://clinicaltrials.gov/study/NCT07505745

Published Studies

Plain-English summaries of the peer-reviewed studies behind the claims above. Click any title to read the source paper.

Cell Metabolism · 2015Open Access via PMC
The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance →

Lee C, Zeng J, Drew BG, et al.

The foundational study that first identified MOTS-c and established its role in metabolic regulation. Researchers found that MOTS-c is encoded by mitochondrial DNA, is released into circulation in response to metabolic stress, and acts on skeletal muscle to improve glucose uptake via AMPK activation. In mice fed a high-fat diet, MOTS-c treatment significantly reduced obesity and insulin resistance without altering food intake.

Nature Communications · 2021Open Access
MOTS-c is an Exercise-Induced Mitochondrial-Encoded Regulator of Age-Dependent Physical Decline and Muscle Homeostasis →

Reynolds JC, Lai RW, Woodhead JST, et al.

This study established MOTS-c as an exercise-induced peptide — showing that MOTS-c levels increase 11.9-fold in skeletal muscle after exercise in humans. MOTS-c treatment significantly enhanced physical performance in young, middle-aged, and old mice — even when treatment was started very late in life (equivalent to human old age). This positions MOTS-c as a potential exercise mimetic for aging populations with limited mobility.

Frontiers in Endocrinology · 2023Open Access
MOTS-c: A Promising Mitochondrial-Derived Peptide for Therapeutic Exploitation →

Zheng Y, Wei Z, Wang T, et al.

A comprehensive review synthesizing a decade of MOTS-c research across multiple disease models. The review covers MOTS-c's mechanisms including AMPK activation, nuclear translocation during stress, anti-inflammatory effects, and insulin sensitization. It documents lower MOTS-c levels in type 2 diabetes, gestational diabetes, and obese children — establishing clinical associations between MOTS-c deficiency and metabolic disease.

Frontiers in Physiology · 2025Open Access
Mitochondria-Derived Peptide MOTS-c Restores Mitochondrial Respiration in Type 2 Diabetic Heart →

Lim YX, et al.

One of the most recent MOTS-c studies, examining its effects in a type 2 diabetic heart model. MOTS-c treatment restored mitochondrial respiratory function, reduced cardiac oxidative stress, and delayed weight gain in diabetic rats — without affecting food intake. The study confirms that MOTS-c directly increases whole-body metabolic rate rather than simply reducing appetite, and extends its relevance to cardiac metabolic function.

MitochondrialInsulin SensitivityAnti-AgingResearch-Grade

Related Peptides

CagrilintideAOD-9604NAD+EpitalonSemaglutide

Related Blends

NAD+ + MOTS-c + 5-Amino-1MQAOD-9604 + MOTS-c

Comparisons

AOD-9604 vs MOTS-C

We may earn commissions from peptide vendor affiliate links.

Have a question about MOTS-c? Send us an email